

Financial news for NUVA dated on 2020-06-05: Wells Fargo Maintains Equal-Weight on NuVasive, Raises Price Target to \$63

Financial news for NUVA dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for NUVA dated on 2020-05-18: Shares of several healthcare companies are trading higher in sympathy with the overall market as optimism around a coronavirus vaccine increased following news from Moderna.

Financial news for NUVA dated on 2020-05-08: Shares of several healthcare companies are trading higher after US unemployment figures came in below consensus estimates. Equities have been strong this week amid a rebound in oil prices and some US states easing lockdown restrictions.

Financial news for NUVA dated on 2020-05-07: Canaccord Genuity Maintains Buy on NuVasive, Lowers Price Target to \$64

Financial news for NUVA dated on 2020-05-07: Citigroup Maintains Neutral on NuVasive, Raises Price Target to \$58

Financial news for NUVA dated on 2020-05-07: UBS Maintains Sell on NuVasive, Lowers Price Target to \$55

Financial news for NUVA dated on 2020-05-06: NuVasive Withdraws Its FY20 Guidance Due To Coronavirus

Financial news for NUVA dated on 2020-05-06: NuVasive Q1 EPS \$0.480 Beats \$0.430 Estimate, Sales \$259.900M Miss \$273.880M Estimate

Financial news for NUVA dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for NUVA dated on 2020-05-04: JP Morgan Maintains Neutral on NuVasive, Lowers Price Target to \$60

Financial news for NUVA dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for NUVA dated on 2020-04-17: Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.

Financial news for NUVA dated on 2020-04-14: NuVasive Withdraws FY20 Guidance

Financial news for NUVA dated on 2020-04-14: NuVasive Sees Q1 Sales \$259M-\$261M vs \$282M Estimate

Financial news for NUVA dated on 2020-04-14: NuVasive Outlines Expense Control Measures Amid Coronavirus Pandemic

Financial news for NUVA dated on 2020-04-08: Benzinga's Top Upgrades, Downgrades For April 8, 2020

Financial news for NUVA dated on 2020-04-08: NuVasive shares are trading higher after Baird upgraded the stock from Neutral to Outperform.

Financial news for NUVA dated on 2020-04-08: Wells Fargo Maintains Equal-Weight on NuVasive, Lowers Price Target to \$56

Financial news for NUVA dated on 2020-04-08: 10 Biggest Price Target Changes For Wednesday

Financial news for NUVA dated on 2020-04-08: Baird Upgrades NuVasive to Outperform, Lowers Price Target to \$66

Financial news for NUVA dated on 2020-04-07: Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for NUVA dated on 2020-03-27: Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers Price Target to \$63

Financial news for NUVA dated on 2020-03-27: Citigroup Maintains Neutral on NuVasive, Lowers Price Target to \$55

Financial news for NUVA dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for NUVA dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for NUVA dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for NUVA dated on 2020-03-13: Stocks That Hit 52-Week Lows On Friday

Financial news for NUVA dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for NUVA dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for NUVA dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for NUVA dated on 2020-03-11: Stocks That Hit 52-Week Lows On Wednesday

Financial news for NUVA dated on 2020-03-06: Credit Suisse Maintains Outperform on NuVasive, Lowers Price Target to \$86

Financial news for NUVA dated on 2020-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2020

Financial news for NUVA dated on 2020-03-05: Citigroup Initiates Coverage On NuVasive with Neutral Rating, Announces \$68 Price Target

Financial news for NUVA dated on 2020-02-21: Cantor Fitzgerald Maintains Neutral on NuVasive, Raises Price Target to \$85

Financial news for NUVA dated on 2020-02-20: NuVasive Sees FY20 Revenue Growth 4-6%, EPS \$2.55-\$2.65 Vs. \$2.60 Est.

Financial news for NUVA dated on 2020-02-20: NuVasive Q4 EPS \$0.73 Beats \$0.64 Estimate, Sales \$310.4M Beat \$304.78M Estimate

Financial news for NUVA dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for NUVA dated on 2020-02-20: Earnings Scheduled For February 20, 2020

Financial news for NUVA dated on 2020-02-16: The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions

Financial news for NUVA dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for NUVA dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for NUVA dated on 2020-01-14: Baird Maintains Neutral on NuVasive, Raises Price Target to \$82

Financial news for NUVA dated on 2020-01-14: The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

Financial news for NUVA dated on 2020-01-13: NuVasive Sees FY2019 Sales \$1.17B vs \$1.16B Est

Financial news for NUVA dated on 2020-01-13: NuVasive Sees Q4 Sales \$310M vs \$304.32M Est

Financial news for NUVA dated on 2020-01-10: Stocks That Hit 52-Week Highs On Friday

Financial news for NUVA dated on 2020-01-10: The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

Financial news for NUVA dated on 2020-01-09: Stocks That Hit 52-Week Highs On Thursday

Financial news for NUVA dated on 2020-01-09: The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

Financial news for NUVA dated on 2020-01-08: NuVasive Is 'A Stock To Watch For In 2020,' SunTrust Says In Bullish Initiation

Financial news for NUVA dated on 2020-01-08: Benzinga's Top Upgrades, Downgrades For January 8, 2020

Financial news for NUVA dated on 2020-01-08: Credit Suisse Maintains Outperform on NuVasive, Raises Price Target to \$87

Financial news for NUVA dated on 2020-01-08: SunTrust Robinson Humphrey Initiates Coverage On NuVasive with Buy Rating, Announces \$93 Price Target

Financial news for NUVA dated on 2020-01-08: The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results

Financial news for NUVA dated on 2020-01-03: The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

Financial news for NUVA dated on 2020-01-02: NuVasive Appoints Matthew K. Harbaugh CFO

Financial news for NUVA dated on 2019-12-26: The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

Financial news for NUVA dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for NUVA dated on 2019-12-23: Stocks That Hit 52-Week Highs On Monday

Financial news for NUVA dated on 2019-12-18: The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

Financial news for NUVA dated on 2019-12-17: Stocks That Hit 52-Week Highs On Tuesday

Financial news for NUVA dated on 2019-12-17: Morgan Stanley Maintains Equal-Weight on NuVasive, Raises Price Target to \$82

Financial news for NUVA dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for NUVA dated on 2019-12-13: SVB Leerink Earlier Maintained Outperform on NuVasive, Raised Price Target to \$92

Financial news for NUVA dated on 2019-12-13: Stocks That Hit 52-Week Highs On Friday

Financial news for NUVA dated on 2019-12-06: Stocks That Hit 52-Week Highs On Friday

Financial news for NUVA dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for NUVA dated on 2019-11-21: NuVasive Reports Receives FDA Clearance For Expanded Multi-Level Use Of CoRoent Small Interlock System For Cervical Spine

Financial news for NUVA dated on 2019-11-18: Stocks That Hit 52-Week Highs On Monday

Financial news for NUVA dated on 2019-10-30: NuVasive Raised FY19 EPS Guidance From \$2.25-\$2.35 To \$2.35-\$2.40 vs \$2.32 Est.

Financial news for NUVA dated on 2019-10-30: NuVasive Raises FY19 Sales Guidance From \$1.14B-\$1.16B To \$1.16B vs \$1.16B Est.

Financial news for NUVA dated on 2019-10-30: NuVasive Q3 EPS \$0.59 Beats \$0.53 Estimate, Sales \$290.8M Beat \$283.76M Estimate

Financial news for NUVA dated on 2019-09-10: UBS Maintains Sell on NuVasive, Raises Price Target to \$55

Financial news for NUVA dated on 2019-09-09: UPDATE: UBS Maintains Sell On NuVasive, Raises Target To \$55 As Firm Notes 'Despite the better recent performance, we remain Sell rated on the shares but are increasing our PT to account for NUVA's momentum and upcoming product launches'

Financial news for NUVA dated on 2019-09-09: UBS Maintains Sell on NuVasive, Raises Price Target to \$55

Financial news for NUVA dated on 2019-09-05: NuVasive Highlights Launch Of Porous Titanium Implant

Financial news for NUVA dated on 2019-08-27: Alphatec Announces Favorable Judgment In NuVasive v. Miles Lawsuit

Financial news for NUVA dated on 2019-08-09: BMO Capital Maintains Market Perform on NuVasive, Raises Price Target to \$68

Financial news for NUVA dated on 2019-08-08: NuVasive Presents Long-Term Strategy and Financial Outlook at 2019 Investor Day

Financial news for NUVA dated on 2019-08-01: 88 Biggest Movers From Yesterday

Financial news for NUVA dated on 2019-07-31: 71 Stocks Moving In Wednesday's Mid-Day Session

Financial news for NUVA dated on 2019-07-31: NuVasive shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for NUVA dated on 2019-07-31: 42 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NUVA dated on 2019-07-31: Morgan Stanley Maintains Equal-Weight on NuVasive, Raises Price Target to \$67

Financial news for NUVA dated on 2019-07-31: 28 Healthcare Stocks Moving In Tuesday's After-Market Session

Financial news for NUVA dated on 2019-07-30: 8 Stocks Moving In Tuesday's After-Hours Session

Financial news for NUVA dated on 2019-07-30: NuVasive shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for NUVA dated on 2019-07-30: NuVasive Q2 Adj. EPS \$0.63 Beats \$0.56 Estimate, Sales \$292.1M Beat \$290.59M Estimate

Financial news for NUVA dated on 2019-07-29: Benzinga's Top Upgrades, Downgrades For July 29, 2019

Financial news for NUVA dated on 2019-07-29: Baird Downgrades NuVasive to Neutral, Announces \$66 Price Target

Financial news for NUVA dated on 2019-07-10: NuVasive Launches Pulse Integrated Technology Platform To Enable Better Spine Surgery

Financial news for NUVA dated on 2019-05-30: NuVasive Reports SpineTRACK Registry Successfully Met 2018 Medicare Reporting Requirements For Merit-Based Incentive Payment System

Financial news for NUVA dated on 2019-05-01: NuVasive Reaffirms FY19 Adj. EPS Guidance Of \$2.20-\$2.30 vs \$2.25 Est., Sales Guidance Of \$1.14B-\$1.16B vs \$1.15B Est.

Financial news for NUVA dated on 2019-05-01: NuVasive Q1 Adj. EPS \$0.53 Beats \$0.41 Estimate, Sales \$274.8M Beat \$269.48M Estimate

Financial news for NUVA dated on 2019-05-01: A Preview Of NuVasive's Q1 Earnings

Financial news for NUVA dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for NUVA dated on 2019-04-22: NuVasive Highlights Publication Of Study Results Of Its PEEK Implant In A Medical Journal

Financial news for NUVA dated on 2019-04-17: Shares of several medical device companies are trading lower with the healthcare sector. Healthcare has seen weakness recently due to concerns over the future of the Affordable Act under Trump and healthcare policy uncertainty ahead of the 2020 election.

Financial news for NUVA dated on 2019-03-13: 56 Biggest Movers From Yesterday

Financial news for NUVA dated on 2019-03-12: 42 Stocks Moving In Tuesday's Mid-Day

Session

Financial news for NUVA dated on 2019-02-20: NuVasive Sees FY19 Adj. EPS \$2.20-\$2.30 vs \$2.47 Estimate, Sales \$1.14B-\$1.16B vs \$1.17B Est.

Financial news for NUVA dated on 2019-02-20: NuVasive Q4 EPS \$0.69 Beats \$0.64 Estimate, Sales \$288.3M Miss \$291.94M Estimate

Financial news for NUVA dated on 2019-02-20: Earnings Scheduled For February 20, 2019

Financial news for NUVA dated on 2019-02-19: NuVasive Reports Its Proprietary Magnetic Implant System Received FDA 510(k) Clearance, CE Mark Approval, Will Be Used In First-Of-Kind All-Internal Bone Transport System

Financial news for NUVA dated on 2019-02-12: Jefferies Downgrades NuVasive, Says M&A Unlikely To Materialize

Financial news for NUVA dated on 2019-02-12: Benzinga's Top Upgrades, Downgrades For February 12, 2019

Financial news for NUVA dated on 2019-02-12: Jefferies Downgrades NuVasive to Hold

Financial news for NUVA dated on 2019-02-12: 54 Biggest Movers From Yesterday

Financial news for NUVA dated on 2019-02-11: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Mon., Feb. 11, 2019

Financial news for NUVA dated on 2019-02-11: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for NUVA dated on 2019-02-11: Mid-Day Market Update: Crude Oil Down Over 2%; NuVasive Shares Spike Higher

Financial news for NUVA dated on 2019-02-11: Mid-Morning Market Update: Markets Edge Higher; Restaurant Brands Beats Q4 Estimates

Financial news for NUVA dated on 2019-02-11: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Monday, February 11, 2019

Financial news for NUVA dated on 2019-02-11: NuVasive shares are trading higher following media reports that Smith & Nephew is in talks to acquire NuVasive for over \$3B.

Financial news for NUVA dated on 2019-02-11: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for NUVA dated on 2019-02-11: A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Financial news for NUVA dated on 2019-02-11: 8 Stocks To Watch For February 11, 2019

Financial news for NUVA dated on 2019-02-08: NuVasive shares are trading higher after a Financial Times report surfaced that detailed Smith & Nephew is in talks to buy NuVasive for over \$3 billion.

Financial news for NUVA dated on 2019-02-08: NuVasive Shares Spike 28% Just Ahead Of Close Amid FT Report 'Smith & Nephew in talks to buy NuVasive for over \$3bn'

Financial news for NUVA dated on 2019-02-08: Needham Downgrades NuVasive to Hold

Financial news for NUVA dated on 2019-01-09: The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brain Cancer Drug Study

Financial news for NUVA dated on 2019-01-08: Stocks Which Set New 52-Week Low Yesterday, Mon., Jan. 7, 2019

Financial news for NUVA dated on 2019-01-08: UBS Maintains Sell on NuVasive, Lowers Price Target to \$42

Financial news for NUVA dated on 2019-01-08: 65 Biggest Movers From Yesterday

Financial news for NUVA dated on 2019-01-07: NuVasive shares are trading lower after the company missed Q4 sales estimates.

Financial news for NUVA dated on 2019-01-07: NuVasive Sees FY2018 Sales \$1.10B vs \$1.11B Est

Financial news for NUVA dated on 2019-01-07: NuVasive Sees Q4 Sales \$288.0M vs \$294.35M Est

Financial news for NUVA dated on 2019-01-02: Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers Price Target to \$57

Financial news for NUVA dated on 2018-12-18: Credit Suisse Initiates Coverage On NuVasive with Outperform Rating, Announces \$66 Price Target

Financial news for NUVA dated on 2018-12-10: NuVasive Announces Receipt Of FDA 501(k) Clearance For Expanded Use Of Its Monolith Corpectomy System

Financial news for NUVA dated on 2018-12-10: NuVasive Receives FDA 510(k) Clearance for Expanded Use of its Monolith Corpectomy System

Financial news for NUVA dated on 2018-11-28: UBS Initiates Coverage On NuVasive with Sell Rating, Announces \$54 Price Target

Financial news for NUVA dated on 2018-11-01: 82 Biggest Movers From Yesterday

Financial news for NUVA dated on 2018-10-31: 66 Stocks Moving In Wednesday's Mid-Day Session

Financial news for NUVA dated on 2018-10-31: BMO Capital Maintains Market Perform on NuVasive, Lowers Price Target to \$68

Financial news for NUVA dated on 2018-10-31: 38 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NUVA dated on 2018-10-30: UPDATE: NuVasive Raises FY18 Sales Guidance From \$1.095B-\$1.105B To \$1.105B-\$1.11B vs \$1.1B Estimate, Cuts Adj. EPS From \$2.37-\$2.40 To \$2.15-\$2.23 vs \$2.38 Est.

Financial news for NUVA dated on 2018-10-30: NuVasive Raises FY18 Sales Guidance, Cuts Adj. EPS Guidance

Financial news for NUVA dated on 2018-10-30: NuVasive Q3 EPS \$0.56 Misses \$0.62 Estimate, Sales \$271.301M Beat \$265.44M Estimate

Financial news for NUVA dated on 2018-10-19: NuVasive Reports J. Christopher Berry To Succeed Gregory Lucier As CEO

Financial news for NUVA dated on 2018-10-09: NuVasive Earlier Announced Strategic Partnership With Biedermann Technologies To Access Intellectual Property And Co-Develop Complex Spine Solutions

Financial news for NUVA dated on 2018-10-08: NuVasive Wins 3-Year Sole Source Supplier contract For Intraoperative Neuromonitoring Services With Premier, No Terms Disclosed

Financial news for NUVA dated on 2018-10-03: Stocks Which Set New 52-Week High Yesterday, October 2nd

Financial news for NUVA dated on 2018-09-27: Baird Upgrades NuVasive to Outperform, Raises Price Target to \$82

Financial news for NUVA dated on 2018-09-26: NuVasive Enrolls First Patients In Long-Term, Controlled Study Evaluating Advanced Implants' Effects On Fusion And Clinical Outcomes In XLIF Procedures

Financial news for NUVA dated on 2018-09-25: 10 Biggest Price Target Changes For Tuesday

Financial news for NUVA dated on 2018-09-25: Morgan Stanley Maintains Equal-Weight on NuVasive, Raises Price Target to \$77

Financial news for NUVA dated on 2018-09-17: Stocks Which Set New 52-Week High Friday, September 14th

Financial news for NUVA dated on 2018-09-17: Canaccord Genuity Maintains Buy on NuVasive, Raises Price Target to \$80

Financial news for NUVA dated on 2018-09-14: Stocks Which Set New 52-Week High Yesterday, September 13th

Financial news for NUVA dated on 2018-09-13: Stocks Which Set New 52-Week High Yesterday, September 12

Financial news for NUVA dated on 2018-09-13: The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

Financial news for NUVA dated on 2018-09-12: Stocks Which Set New 52-Week High Yesterday, September 11th

Financial news for NUVA dated on 2018-08-24: Stocks Which Set New 52-Week High Yesterday, August 23rd

Financial news for NUVA dated on 2018-08-17: Stocks Which Set New 52-Week High Yesterday, August 16th

Financial news for NUVA dated on 2018-08-09: NuVasive Reports Partnership With Siemens Related To Spine Surgery, No Terms Disclosed

Financial news for NUVA dated on 2018-07-31: UPDATE: NuVasive Cuts FY18 Adj. EPS From \$2.44-\$2.47 To \$2.37-\$2.40 vs \$2.44 Estimate, Reaffirms Sales Guidance \$1.095B-\$1.105B vs \$1.1B Est.

Financial news for NUVA dated on 2018-07-31: NuVasive Cuts FY18 Guidance

Financial news for NUVA dated on 2018-07-31: NuVasive Q2 EPS \$0.58, Inline, Sales \$281.564M Beat \$276.26M Estimate

Financial news for NUVA dated on 2018-07-31: Earnings Scheduled For July 31, 2018

Financial news for NUVA dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for NUVA dated on 2018-07-19: Nuvasive Earlier Launched MAGEC X For Early Onset Scoliosis Treatment

Financial news for NUVA dated on 2018-07-16: NuVasive Earlier Introduced Low-Profile Modular Implants For Posterior Fixation

Financial news for NUVA dated on 2018-07-10: NuVasive Unveils XLIF Lordotic Expandable Interbody System, Which Received FDA 510(k) Clearance at IMAST 2018

Financial news for NUVA dated on 2018-06-21: JP Morgan Downgrades NuVasive to Neutral

Financial news for NUVA dated on 2018-06-20: First Porous PEEK Spinal Implant Clinical Study Validates NuVasive Advanced Materials Science Technology In Treating Degenerative Cervical Disc Disease

Financial news for NUVA dated on 2018-06-12: NuVasive Launches AttraX Scaffold Biologic Bone Graft With Optimized Surface To Drive Increased Bone Formation And Reports First Clinical Use

Financial news for NUVA dated on 2018-06-03: Cantor Fitzgerald Taps Spinal Stocks: 4 Top Picks

Financial news for NUVA dated on 2018-06-01: Benzinga's Top Upgrades, Downgrades For June 1, 2018

Financial news for NUVA dated on 2018-06-01: Cantor Fitzgerald Initiates Coverage On NuVasive with Neutral Rating, Announces \$54 Price Target

Financial news for NUVA dated on 2018-05-02: Benzinga's Top Upgrades, Downgrades For May 2, 2018

Financial news for NUVA dated on 2018-05-02: BMO Capital Downgrades NuVasive to Market Perform

Financial news for NUVA dated on 2018-05-01: NuVasive Reaffirms FY18 Adj. EPS Outlook \$2.44-\$2.47 vs \$2.46 Est., Sales \$1.095B-\$1.105B vs \$1.1B Est.

Financial news for NUVA dated on 2018-05-01: NuVasive Reports Q1 2018 EPS of \$0.39 vs \$0.45 Est Revenue of \$260.5M vs \$259.49M Est

Financial news for NUVA dated on 2018-04-04: Goldman Sachs Initiates Coverage On NuVasive with Neutral Rating, Announces \$47.00 Price Target

Financial news for NUVA dated on 2018-02-27: Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers price target to \$55.00

Financial news for NUVA dated on 2018-02-27: Leerink Swann Maintains Market Perform on NuVasive, Raises Price Target to \$52.00

Financial news for NUVA dated on 2018-02-26: NuVasive Sees FY18 Adj. EPS \$2.44-\$2.47 vs \$2.37 Est., Sales \$1.095B-\$1.105B vs \$1.09B Est.

Financial news for NUVA dated on 2018-02-26: NuVasive Reports Q4 Adj. EPS \$0.56 vs \$0.45 Est., Sales \$271.7M vs \$258.8M Est.

Financial news for NUVA dated on 2018-02-26: Earnings Scheduled For February 26, 2018

Financial news for NUVA dated on 2018-02-14: 13F From Rosenstein's JANA Shows Liquidated Stake In NuVasive

Financial news for NUVA dated on 2018-02-01: Benzinga's Top Upgrades, Downgrades For February 1, 2018

Financial news for NUVA dated on 2018-02-01: The Market In 5 Minutes: Facebook Earnings, Jobless Claims Fall, Wynn Fallout

Financial news for NUVA dated on 2018-02-01: Leerink Swann Downgrades NuVasive to Market Perform

Financial news for NUVA dated on 2018-01-17: Benzinga's Top Upgrades, Downgrades For January 17, 2018

Financial news for NUVA dated on 2018-01-17: Wells Fargo Downgrades NuVasive to Market Perform

Financial news for NUVA dated on 2018-01-08: Mid-Afternoon Market Update: NASDAQ Gains 0.2%; GoPro Shares Spike Higher

Financial news for NUVA dated on 2018-01-08: NuVasive Sees Q4 Sales ~\$272M vs \$272.9M Est.; Sees FY17 Sales ~\$1.03B vs \$1.03B Est.

Financial news for NUVA dated on 2017-12-12: NuVasive To Acquire SafePassage, No Terms Disclosed

Financial news for NUVA dated on 2017-11-14: 13F Filing Shows Jana Partners Exited Home Depot and Hewlett Packard Enterprise Stakes, Reduced Gardner Denver and NuVasive Stakes

Financial news for NUVA dated on 2017-10-24: NuVasive Lowers FY17 Adj. EPS Outlook From \$2.00 to \$1.91 vs \$1.99 Est., Sales From \$1.065B to \$1.03B vs \$1.06B Est.

Financial news for NUVA dated on 2017-10-24: NuVasive Reports Q3 Adj. EPS \$0.52 vs \$0.48 Est., Sales \$247.4M vs \$255.36M Est.

Financial news for NUVA dated on 2017-10-24: NuVasive Announces \$100M Share Buyback

Financial news for NUVA dated on 2017-10-18: NuVasive Highlights Launch Of 3D-Printed Porous Titanium Implant, Modulus XLIF

Financial news for NUVA dated on 2017-10-16: NuVasive Receives Expanded 510(k) Clearance For TLX Interbody System Used In TLIF Procedures

Financial news for NUVA dated on 2017-10-12: NuVasive Reports Expanded FDA 510(k) Clearance For PRECICE System

Financial news for NUVA dated on 2017-10-11: Alphatec Issues Release Denouncing 'Baseless' NuVasive Complaint

Financial news for NUVA dated on 2017-10-10: NuVasive Files Lawsuit Against Its Fmr. Chairman Patrick Miles Alleging Miles Engaged In Scheme To Divert Corporate Opportunities

Financial news for NUVA dated on 2017-09-22: NuVasive Holding Mainstay Annual General Meeting Today

Financial news for NUVA dated on 2017-09-20: The Market In 5 Minutes

Financial news for NUVA dated on 2017-09-19: GlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors

Financial news for NUVA dated on 2017-09-19: UPDATE: GlassHouse Sets \$24.18 Price Target On NuVasive Shares, Representing Possible Downside Of ~57% From Current Levels

Financial news for NUVA dated on 2017-09-19: UPDATE: GlassHouse On NuVasive Highlights Recent Pres/COO, CFO Departures, Warns Co. Has 'Similar Accounting Concerns To Electronics For Imaging'

Financial news for NUVA dated on 2017-09-19: GlassHouse Research Issues Negative Research Report On NuVasive

Financial news for NUVA dated on 2017-09-08: Wall Street's M&A Chatter From September

7: Amcor-Bemis, NuVasive-Vertera Spine, Newell-Chesapeake Bay Candle

Financial news for NUVA dated on 2017-09-07: NuVasive Announces Acquisition Of Vertera Spine, Terms Not Disclosed

Financial news for NUVA dated on 2017-09-06: Nuvasive Receives 510(K) Clearance For Leading EOS Innovation

Financial news for NUVA dated on 2017-08-28: Benzinga's Top Upgrades, Downgrades For August 28, 2017

Financial news for NUVA dated on 2017-08-28: Needham Downgrades NuVasive to Underperform

Financial news for NUVA dated on 2017-08-15: NuVasive Names Rajesh J. Asarpota CFO

Financial news for NUVA dated on 2017-07-28: 20 Biggest Mid-Day Losers For Friday

Financial news for NUVA dated on 2017-07-28: Benzinga's Top Upgrades, Downgrades For July 28, 2017

Financial news for NUVA dated on 2017-07-28: Baird Downgrades NuVasive to Neutral

Financial news for NUVA dated on 2017-07-28: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for NUVA dated on 2017-07-27: NuVasive Sees FY17 EPS \$2.00 vs \$2.01 Est., Sales \$1.065B vs \$1.07B Est.

Financial news for NUVA dated on 2017-07-27: NuVasive Announces Resignation of CFO Quentin Blackford, President And COO Jason Hannon

Financial news for NUVA dated on 2017-07-27: NuVasive Reports Q2 Adj. EPS \$0.46 vs \$0.44 Est., Sales \$260.6M vs \$262M Est.

Financial news for NUVA dated on 2017-04-26: Buy The Dip In NuVasive Shares, Says Canaccord Genuity

Financial news for NUVA dated on 2017-04-26: NuVasive Shares Down ~5% Following Mixed Q1 Results, Soft FY17 Outlook; Canaccord Earlier Said 'We Would Be Buyers on Any Weakness,' Raised Price Target from \$82 to \$84

Financial news for NUVA dated on 2017-04-25: NuVasive Sees FY17 Sales ~\$1.065B vs \$1.07B Est., EPS ~\$2.00 vs \$2.02 Est.

Financial news for NUVA dated on 2017-04-25: NuVasive Reports Q1 EPS \$0.38 vs \$0.38 Est., Sales \$250M vs \$250.8M Est.

Financial news for NUVA dated on 2017-03-29: NuVasive Reports Received FDA Clearance for Cervical Interbody Implant System

Financial news for NUVA dated on 2017-02-09: NuVasive Reports Q4 EPS \$0.53 vs. Est. \$0.51, Rev. \$271.1M vs. Est. \$261M

Financial news for NUVA dated on 2017-01-09: Nuvasive Sees FY16 Rev. ~\$956M vs. Est. \$952M, FY17 Rev. \$1.065B vs. Est. \$1.07B

Financial news for NUVA dated on 2016-12-29: NuVasive Will Resume XLIF Procedures in Japan in Q1

Financial news for NUVA dated on 2016-12-01: 10 Stocks That Rallied Four Days, Then Sold Off Yesterday

Financial news for NUVA dated on 2016-11-30: Benzinga's Top Initiations

Financial news for NUVA dated on 2016-11-30: Aegis Capital Initiates Coverage On NuVasive at Buy, Announces \$72.00 Target

Financial news for NUVA dated on 2016-11-03: Insiders Take Advantage Of NuVasive Pullback After Earnings

Financial news for NUVA dated on 2016-10-27: NuVasive Secures Magnetic Resonance (MR) FDA Conditional Clearance for MAGEC System

Financial news for NUVA dated on 2016-10-27: 15 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for NUVA dated on 2016-10-25: NuVasive Reaffirms FY16 Sales ~\$952M vs \$962.4M Est., Adj. EPS ~\$1.64 vs \$1.65 Est.

Financial news for NUVA dated on 2016-10-25: NuVasive Reports Q3 EPS \$0.40 vs. Est. \$0.40, Rev. \$239.6M vs. Est. \$243.5M

Financial news for NUVA dated on 2016-10-18: NuVasive Postpones Q3 Earnings Announcement From Wednesday Oct. 26 To Tuesday Oct. 25th

Financial news for NUVA dated on 2016-09-23: 20 Stocks Which Rallied Three Days On Increasing Volume

Financial news for NUVA dated on 2016-09-21: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for NUVA dated on 2016-09-21: Benzinga's Volume Movers

Financial news for NUVA dated on 2016-09-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NUVA dated on 2016-09-20: S&P Dow Jones Indices Announces 'The Cooper Companies Set to Join the S&P 500; Northwestern and NuVasive to Join S&P MidCap 400; SPS Commerce and Fox Factory to Join S&P SmallCap 600'

Financial news for NUVA dated on 2016-09-19: NuVasive Gets FDA 501(k) Clearance - Dow Jones

Financial news for NUVA dated on 2016-09-13: The Market In 5 Minutes: The Fed And IEA Confuse The Market

Financial news for NUVA dated on 2016-09-12: NuVasive Reaffirms FY16 Outlook: Adj. EPS \$1.64 vs \$1.65 Est., Sales \$962M vs \$962.4M Est.

Financial news for NUVA dated on 2016-09-12: NuVasive Names Jason Hannon Pres, COO; Patrick Miles Will Assume Role of Vice Chair

Financial news for NUVA dated on 2016-08-16: Here Are All The CEOs Benzinga Spoke With In 2016

Financial news for NUVA dated on 2016-07-26: After-Market Gainers: AAPL Up 6.06%, SWKS 2.44%, QROV 2.80%, PNRA 4.54%, LOGM 19.48%, EW 6.56%, JBT 2.53%, NUVA 2.10%

Financial news for NUVA dated on 2016-07-26: NuVasive Reports Q2 Adj. EPS \$0.40 vs \$0.36 Est.

Financial news for NUVA dated on 2016-07-13: 7 Largest Price Target Changes For Wednesday

Financial news for NUVA dated on 2016-07-13: Benzinga's Top Upgrades

Financial news for NUVA dated on 2016-07-13: JPMorgan Sees Double-Digit Sales Ahead For NuVasive, Upgrades To Overweight

Financial news for NUVA dated on 2016-07-13: JP Morgan Upgrades NuVasive to Overweight, Raises PT to \$74.00

Financial news for NUVA dated on 2016-06-30: NuVasive Agrees to Settle Patent Litigation With Medtronic, NuVasive To Make One-Time Payment Of \$45M To Medtronic

Financial news for NUVA dated on 2016-06-14: Exclusive: NuVasive CEO Talks M&A, Brazil, And The Company's Biggest Weakness

Financial news for NUVA dated on 2016-06-14: NuVasive CEO At William Blair Conf. Says Company Sees Operating Margins At 15.8% Due To Some Headwinds From Recent Acquisition

Financial news for NUVA dated on 2016-06-06: NuVasive to Buy Biotronic NeuroNetwork for \$98M in Cash

Financial news for NUVA dated on 2016-05-27: Barclays Bullish On NuVasive, Globus Medical, Dislikes LDR Holding

Financial news for NUVA dated on 2016-05-27: Benzinga's Top Upgrades

Financial news for NUVA dated on 2016-05-27: The Market In 5 Minutes: Happy Memorial Day Weekend

Financial news for NUVA dated on 2016-05-27: Barclays Upgrades NuVasive to Overweight, Raises PT to \$63.00

Financial news for NUVA dated on 2016-04-27: Cowen & Company Maintains Outperform on NuVasive, Raises PT to \$63.00

Financial news for NUVA dated on 2016-04-26: NuVasive Sees FY16 Rev. ~\$928M vs. Est. \$924M, EPS ~\$1.48 vs. Est. \$1.49

Financial news for NUVA dated on 2016-04-26: NuVasive Reports Q1 EPS \$0.31 vs. Est. \$0.27, Rev. \$215.1M vs. Est. \$205.67M

Financial news for NUVA dated on 2016-03-09: NuVasive Reports Regulatory Approval of reline Posterior Fixation Technology in Japan

Financial news for NUVA dated on 2016-03-08: The Market In 5 Minutes: Tuesday, March 8, 2016

Financial news for NUVA dated on 2016-03-07: NuVasive Reports Deal to Buy Mega Surgical, No Terms Disclosed

Financial news for NUVA dated on 2016-02-11: NuVasive Sees FY16 Sales ~\$923M vs \$881M Est., Adj. EPS ~\$1.48 vs \$1.49 Est.

Financial news for NUVA dated on 2016-02-11: NuVasive Reports Q4 Adj. EPS \$0.35 vs \$0.31 Est., Sales \$215.3M vs \$215.3M Est.

Financial news for NUVA dated on 2016-01-12: NuVasive Sees Q4 Sales \$215.0M vs \$214.98M Est

Financial news for NUVA dated on 2016-01-12: NuVasive Sees FY2016 Sales \$870.0M vs \$880.98M Est

Financial news for NUVA dated on 2016-01-12: NuVasive Sees FY2015 Sales \$811.0M vs \$813.71M Est

Financial news for NUVA dated on 2016-01-06: NuVasive Announces Acquisition Of Ellipse Technologies, Notes 'Potential To Become The Standard Of Care'

Financial news for NUVA dated on 2016-01-05: NuVasive To Acquire Ellipse Technologies For \$380M Cash And \$30M Milestone Potential

Financial news for NUVA dated on 2015-12-11: Benzinga's Top Upgrades

Financial news for NUVA dated on 2015-12-11: Bank of America Upgrades NuVasive to Neutral

Financial news for NUVA dated on 2015-12-10: Nuvasive In 8-K, Reiterates FY15 Rev. Guidance Of \$810M vs. Est. \$811.01M, Sees FY16 Rev. \$870M vs. Est. \$871.24M

Financial news for NUVA dated on 2015-10-27: Nuvasive Earlier Saw FY15 Rev. ~\$810M vs. Est. \$813.34M, EPS ~\$1.25 vs. Est. \$1.19

Financial news for NUVA dated on 2015-10-27: NuVasive Reports Q3 EPS \$0.35 vs. Est. \$0.27, Rev. \$200.5M vs. Est. \$200.2M

Financial news for NUVA dated on 2015-10-12: NuVasive Receives First Ever FDA 510(k) Clearance of Cervical Corpectomy Cage

Financial news for NUVA dated on 2015-10-06: Benzinga's Top Upgrades

Financial news for NUVA dated on 2015-10-06: NuVasive Upgraded To Buy At Canaccord On Leverage

Financial news for NUVA dated on 2015-07-29: Northland Securities Upgrades NuVasive to Outperform, Raises PT to \$68.00

Financial news for NUVA dated on 2015-07-29: Brean Capital Maintains Buy on NuVasive, Raises PT to \$56.00

Financial news for NUVA dated on 2015-07-28: UPDATE: NuVasive Raises FY15 Adj. EPS from \$1.10 to ~\$1.17 vs \$1.12 Est., Sales ~\$810M vs \$812M Est.

Financial news for NUVA dated on 2015-07-28: NuVasive Reports Q2 Adj. EPS \$0.31 vs \$0.25 Est., Sales \$202.9M vs \$200.7M Est.; Raises FY15 Outlook

Financial news for NUVA dated on 2015-07-28: NuVasive Reports Settlement With U.S.

Financial news for NUVA dated on 2015-07-13: NuVasive Names Pat Miles COO, Quentin Blackford CFO

Financial news for NUVA dated on 2015-06-11: Nuvasive Chairman Lucier Buys 10,000 Shares @\$49.10/Share -Form 4

Financial news for NUVA dated on 2015-06-11: Piper Jaffray Met With NuVasive

Management And Came Away 'Still Confident'

Financial news for NUVA dated on 2015-06-03: Goldman Sachs' New Pair Trade? Bull Zeltiq Aesthetics, Bear NuVasive

Financial news for NUVA dated on 2015-06-03: Morning Market Losers

Financial news for NUVA dated on 2015-06-03: Benzinga's Top Downgrades

Financial news for NUVA dated on 2015-06-03: Goldman Sachs Downgrades NuVasive To Neutral

Financial news for NUVA dated on 2015-06-03: Benzinga's Top #PreMarket Losers

Financial news for NUVA dated on 2015-06-03: Goldman Sachs Downgrades NuVasive to Neutral

Financial news for NUVA dated on 2015-05-26: NuVasive Names Gregory Lucier CEO

Financial news for NUVA dated on 2015-05-04: NuVasive Reports Q1 EPS \$0.61 Vs Est \$0.22, May Not Compare, Sales \$192.4M Vs Est \$189.30M

Financial news for NUVA dated on 2015-05-04: Earnings Scheduled For May 4, 2015

Financial news for NUVA dated on 2015-04-29: NuVasive Reports Deal in Principle to Settle OIG Matter, Will Pay \$13.8M to US

Financial news for NUVA dated on 2015-04-15: Canaccord Just Downgraded NuVasive And Shares Are Falling

Financial news for NUVA dated on 2015-04-15: Benzinga's Top Downgrades

Financial news for NUVA dated on 2015-04-15: Canaccord Genuity Downgrades NuVasive To Hold

Financial news for NUVA dated on 2015-04-15: Canaccord Genuity Downgrades NuVasive to Hold, Lowers PT to \$49.00

Financial news for NUVA dated on 2015-04-13: Jefferies: 10 Buyout Targets To Own During The M&A Boom

Financial news for NUVA dated on 2015-04-02: Bank of America Downgrades NuVasive to Underperform

Financial news for NUVA dated on 2015-04-01: Shares of NuVasive to Resume Trade at 9 a.m. EDT

Financial news for NUVA dated on 2015-04-01: NuVasive Expecting Q1 Sales \$190M+ vs \$189.3M Est.

Financial news for NUVA dated on 2015-04-01: NuVasive Announces Leadership Transition: Chair, CEO Alex Lukianov to Step Down, Gregory Lucier Named as Replacement

Financial news for NUVA dated on 2015-04-01: Shares of NuVasive Halted News Pending

Financial news for NUVA dated on 2015-03-03: NuVasive Announces Successful Appeal of Medtronic Verdict

Financial news for NUVA dated on 2015-01-12: NuVasive Reports COO Keith Valentine to Resign; Pat Miles Named as Pres, COO

Financial news for NUVA dated on 2015-01-12: NuVasive Sees FY2015 Sales \$810.0M vs \$811.70M Est

Financial news for NUVA dated on 2015-01-12: NuVasive Reports Prelim. FY2014 Sales \$761.0M vs \$758.0M Est

Financial news for NUVA dated on 2015-01-08: RBC Capital Upgrades NuVasive to Outperform, Raises PT to \$56.00

Financial news for NUVA dated on 2014-12-04: Brean Capital Reiterates Buy on NuVasive, Inc., Raises PT to \$53.00

Financial news for NUVA dated on 2014-11-17: Wells Fargo Upgrades NuVasive, Inc. to Outperform

Financial news for NUVA dated on 2014-11-10: NuVasive Focused On Surgeon Support And Showcasing Industry-Leading Products At North American Spine Society 29th Annual

Meeting

Financial news for NUVA dated on 2014-10-30: NuVasive, Inc. Sees FY2014 EPS \$1.12 vs \$1.12 Est; Sees Sales \$755.0M-755.00 vs \$748.0M Est

Financial news for NUVA dated on 2014-10-30: NuVasive, Inc. Reports Q3 EPS of \$0.19 vs \$0.25 Est

Financial news for NUVA dated on 2014-07-29: NuVasive Reports Q2 Adj. EPS \$0.28 vs \$0.25; Raises FY EPS Guidance from ~\$1.06 to ~\$1.11, Sales from ~\$725M to ~\$745M

Financial news for NUVA dated on 2014-07-29: NuVasive Reports Q2 EPS loss \$0.09, Revenues \$190.7M

Financial news for NUVA dated on 2014-05-21: Benzinga's Top Downgrades

Financial news for NUVA dated on 2014-05-21: Needham Downgrades NuVasive, Inc. to Hold, Removes \$40.00 PT

Financial news for NUVA dated on 2014-05-06: NuVasive Announces Favorable Settlement with Cadwell

Financial news for NUVA dated on 2014-04-29: NuVasive Announces CFO Lambert Intends to Retire, Blackford to Succeed

Financial news for NUVA dated on 2014-04-29: NuVasive, Inc. Reports Q1 EPS of \$0.29 vs \$0.23 Est; Revenue of \$177.50M vs \$171.34M Est

Financial news for NUVA dated on 2014-04-04: NuVasive Announces \$30M Unfavorable Jury Verdict for Use of Trade-Name 'NeuroVision' 8-K

Financial news for NUVA dated on 2014-03-03: NuVasive, Inc. Reports Q4 EPS of \$0.37 vs \$0.32 Est; Revenue of \$190.80M vs \$181.24M Est

Financial news for NUVA dated on 2014-03-03: Earnings Scheduled For March 3, 2014

Financial news for NUVA dated on 2014-01-22: Leerink Swann Upgrades NuVasive, Inc. to Outperform, Raises PT to \$45.00

Financial news for NUVA dated on 2014-01-16: Stocks Hitting 52-Week Highs

Financial news for NUVA dated on 2014-01-16: Goldman Sachs Upgrades NuVasive, Inc. to Neutral

Financial news for NUVA dated on 2014-01-15: Market Wrap For January 15: Bulls Take Over As Economic Growth Remains Healthy

Financial news for NUVA dated on 2014-01-15: Mid-Afternoon Market Update: Markets Nearly Erase Early Year Losses as The ExOne Continues to Drop

Financial news for NUVA dated on 2014-01-15: Mid-Day Market Update: Dow Jumps 120 Points; Fastenal Shares Drop On Downbeat Earnings

Financial news for NUVA dated on 2014-01-15: Mid-Morning Market Update: Markets Rise; Bank of America Profit Beats Estimates

Financial news for NUVA dated on 2014-01-15: Benzinga's Volume Movers

Financial news for NUVA dated on 2014-01-15: NuVasive Reports Q4 Prelim. Sales \$189M, FY13 Sales \$683M, FY14 Sales ~\$725M

Financial news for NUVA dated on 2013-12-17: NuVasive Announces US Launch of ALIF ACR(TM)

Financial news for NUVA dated on 2013-12-04: NuVasive Names Gregory Lucier to Board

Financial news for NUVA dated on 2013-10-30: Stocks Hitting 52-Week Highs

Financial news for NUVA dated on 2013-10-29: NuVasive, Inc. Raises FY2013 EPS Guidance from \$1.00 to \$1.14 vs \$1.00 Est; Raises FY2013 Sales Guidance from \$655.0M to \$670.0M vs \$657.90M Est

Financial news for NUVA dated on 2013-10-29: NuVasive, Inc. Reports Q3 EPS of \$0.16 vs \$0.24 Est; Revenue of \$169.20M vs \$158.48M Est

Financial news for NUVA dated on 2013-10-14: UPDATE: Goldman Sachs Downgrades NuVasive as Industry Headwinds, Valuation Pose Downside Risk

Financial news for NUVA dated on 2013-10-14: BMO Capital Upgrades NuVasive, Inc. to

Market Perform, Raises PT to \$25.00

Financial news for NUVA dated on 2013-10-14: Benzinga's Top Downgrades

Financial news for NUVA dated on 2013-10-14: Goldman Sachs Downgrades NuVasive, Inc. to Sell, Lowers PT to \$22.00

Financial news for NUVA dated on 2013-08-08: Benzinga's Top Initiations

Financial news for NUVA dated on 2013-08-08: Needham Initiates Coverage on NuVasive, Inc. at Buy, Announces \$28.00 PT

Financial news for NUVA dated on 2013-07-31: Market Wrap For Wednesday, July 31: Stocks Mostly Unchanged Despite Upbeat Data

Financial news for NUVA dated on 2013-07-31: Mid-Afternoon Market Update: Fed Leaves Rates Unchanged; Green Dot Rises

Financial news for NUVA dated on 2013-07-31: First Analysis Downgraded NuVasive, Inc. to Equalweight, Maintains \$25 PT

Financial news for NUVA dated on 2013-07-31: NuVasive Receives Subpoena from Office of Inspector General of US Department of Health and Human Services -10Q

Financial news for NUVA dated on 2013-07-30: NuVasive, Inc. Reports Q2 EPS of \$0.20 vs \$0.24 Est; Revenue of \$165.70M

Financial news for NUVA dated on 2013-07-25: Janney Capital Downgrades NuVasive to Neutral, Raises PT to \$28.00

Financial news for NUVA dated on 2013-07-15: UPDATE: BMO Capital Markets Downgrades NuVasive on Multiple Positive Factors

Financial news for NUVA dated on 2013-06-19: UPDATE: Canaccord Genuity Raises PT on NuVasive on Multiple Positive Factors

Financial news for NUVA dated on 2013-05-21: UPDATE: Barrington Raises PT on NuVasive on Multiple Positive Factors

Financial news for NUVA dated on 2013-05-17: Wallachbeth Capital Initiates Coverage on NuVasive, Inc. at Buy, Announces \$27.00 PT

Financial news for NUVA dated on 2013-05-06: NuVasive Buys ANC, LLC, Spine Implant Manufacturer for \$4.5M

Financial news for NUVA dated on 2013-05-04: Starbucks, Huntington Bancshares and Other Stocks Insiders Are Buying

Financial news for NUVA dated on 2013-04-30: NuVasive, Inc. Reports Q1 EPS of \$0.02 vs \$0.22 Est; Revenue of \$159.50M vs \$157.44M Est

Financial news for NUVA dated on 2013-03-18: NuVasive Received FDA Warning Letter Related to San Diego Plant

Financial news for NUVA dated on 2013-02-27: UPDATE: J.P. Morgan Raises PT on NuVasive Despite Limited Growth Expectations

Financial news for NUVA dated on 2013-02-27: UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on NuVasive on 4Q2012 Revenue

Financial news for NUVA dated on 2013-02-27: UPDATE: Piper Jaffray Raises PT to \$24 on NuVasive; Q4 Sets Stage for Outperformance

Financial news for NUVA dated on 2013-02-27: UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on NuVasive Following Q4/12 Results

Financial news for NUVA dated on 2013-02-27: Mizuho Securities Downgraded NuVasive, Inc. to Neutral, Maintains \$20.00 PT

Financial news for NUVA dated on 2013-02-27: UPDATE: BMO Capital Markets Raises PT on NuVasive on In-Line 4Q12

Financial news for NUVA dated on 2013-02-27: Goldman Sachs Maintains Neutral on NuVasive, Inc., Raises PT to \$20.00

Financial news for NUVA dated on 2013-02-27: Piper Jaffray Maintains Overweight on NuVasive, Inc., Raises PT to \$24.00

Financial news for NUVA dated on 2013-02-27: JP Morgan Maintains Neutral on NuVasive,

Inc., Raises PT to \$21.00

Financial news for NUVA dated on 2013-02-27: Canaccord Genuity Maintains Buy on NuVasive, Inc., Raises PT to \$25.00

Financial news for NUVA dated on 2013-02-27: BMO Capital Maintains Market Perform on NuVasive, Inc., Raises PT to \$18.00

Financial news for NUVA dated on 2013-02-26: NuVasive, Inc. Reports Q4 EPS of \$0.34 vs \$0.21 Est; Revenue of \$165.80M vs \$157.30M Est

Financial news for NUVA dated on 2013-02-26: NuVasive Announces First Patient in Japan Treated with XLIF(R) Technique

Financial news for NUVA dated on 2013-02-26: UPDATE: JP Morgan Raises PT to \$20 on NuVasive; 2013 Outlook Likely Conservative

Financial news for NUVA dated on 2013-02-26: JP Morgan Maintains Neutral on NuVasive, Inc., Raises PT to \$20.00

Financial news for NUVA dated on 2013-02-26: Earnings Scheduled For February 26, 2013

Financial news for NUVA dated on 2013-01-09: Mid-Afternoon Market Update: NuVasive Rises While EXCO Resourced Drops

Financial news for NUVA dated on 2013-01-09: Mid-Day Market Update: Markets Remain Up, Dynavax Continues Rally

Financial news for NUVA dated on 2013-01-09: Nuvasive Reports Prelim. FY12 Sales ~\$619M vs \$604.4M, Had Seen \$601-606M; Sees FY13 Sales ~\$655M vs \$638M EST

Financial news for NUVA dated on 2013-01-09: Benzinga's Top Upgrades

Financial news for NUVA dated on 2013-01-04: UPDATE: BMO Capital Markets Upgrades Nuvasive to Market Perform, Raises PT

Financial news for NUVA dated on 2013-01-04: BMO Capital Upgrades NuVasive, Inc. to Market Perform, Raises PT to \$17.00

Financial news for NUVA dated on 2012-12-20: NuVasive Announces First Patient in the United States Treated With the PCM Cervical Disc Following FDA Approval

Financial news for NUVA dated on 2012-12-17: NuVasive Wins Regulatory Shonin Approval to Broaden Offering in Japan

Financial news for NUVA dated on 2012-12-13: NuVasive(R) Announces Release of \$62.5M From Escrow Following Appeals Court Victory

Financial news for NUVA dated on 2012-12-13: NuVasive to Release \$62.5M from Escrow Following Appeals Court Win

Financial news for NUVA dated on 2012-11-16: First Analysis Upgraded NuVasive from Equal-weight to Overweight

Financial news for NUVA dated on 2012-10-26: Nuvasive Resumes Trading

Financial news for NUVA dated on 2012-10-26: PREVIEW: NuVasive to Resume Trading at 12:30pm

Financial news for NUVA dated on 2012-10-26: NuVasive Announces PMA Approval of the PCM(R) Cervical Disc System

Financial news for NUVA dated on 2012-10-26: Nuvasive Halted Pending News

Financial news for NUVA dated on 2012-10-25: Leerink Swann Downgraded NuVasive from Outperform to Market Perform

Financial news for NUVA dated on 2012-10-25: Benzinga's Top Downgrades

Financial news for NUVA dated on 2012-10-24: UPDATE: Goldman Sachs Reduces PT to \$16 on NuVasive on Sales Outlook

Financial news for NUVA dated on 2012-10-24: Goldman Sachs Maintains NuVasive at Neutral, Lowers PT from \$17 to \$16

Financial news for NUVA dated on 2012-10-08: From Earlier: Nuvasive's President of Global Sales Resigned

Financial news for NUVA dated on 2012-10-05: JP Morgan Maintains NuVasive at

Neutral, Lowers PT from \$28 to \$21

Financial news for NUVA dated on 2012-10-04: Benzinga Mid-Afternoon Market Update

Financial news for NUVA dated on 2012-10-04: UPDATE: BMO Capital Markets Downgrades NuVasive to Underperform on Outlook

Financial news for NUVA dated on 2012-10-04: Benzinga Mid-Day Market Update

Financial news for NUVA dated on 2012-10-04: Benzinga Mid-Morning Market Update

Financial news for NUVA dated on 2012-10-04: Morning Market Losers

Financial news for NUVA dated on 2012-10-04: RBC Capital Markets Downgraded NuVasive from Outperform to Underperform

Financial news for NUVA dated on 2012-10-04: Wells Fargo Downgraded NuVasive from Outperform to Market Perform

Financial news for NUVA dated on 2012-10-04: Brean Murray Carret Downgraded NuVasive from Buy to Hold

Financial news for NUVA dated on 2012-10-04: BMO Capital Markets Downgrades NuVasive from Market Perform to Underperform, Lowers PT from \$23 to \$15

Financial news for NUVA dated on 2012-10-04: Benzinga's Top Pre-Market Losers

Financial news for NUVA dated on 2012-10-04: Nuvasive Falls 30% Pre-Market on Lowered Guidance

Financial news for NUVA dated on 2012-10-04: Benzinga's Top Downgrades

Financial news for NUVA dated on 2012-10-04: Goldman Sachs Maintains NuVasive at Neutral, Lowers PT from \$23 to \$19

Financial news for NUVA dated on 2012-10-04: Canaccord Maintains NuVasive at Buy, Lowers PT from \$27 to \$21

Financial news for NUVA dated on 2012-10-04: US Stock Futures Up; Jobless Claims, ECB Meeting In Focus

Financial news for NUVA dated on 2012-10-04: Stocks To Watch For October 4, 2012

Financial news for NUVA dated on 2012-10-03: Nuvasive Falls 21% After-Hours on Lowered Guidance

Financial news for NUVA dated on 2012-10-03: UPDATE: NuVasive Guides Q3 Prelim Revenue \$147M, Had Seen \$154.4M vs \$153.4M Est

Financial news for NUVA dated on 2012-10-03: NuVasive Cuts Q3 Prelim Revenue, Forecast \$147M

Financial news for NUVA dated on 2012-10-01: Esterline, Janus Capital and Other Stocks Insiders Are Buying

Financial news for NUVA dated on 2012-07-26: Barclays Maintains NuVasive at Overweight, Raises PT from \$25 to \$27

Financial news for NUVA dated on 2012-07-26: UPDATE: Jefferies Increases PT on NuVasive from \$20 to \$27

Financial news for NUVA dated on 2012-07-26: Jefferies & Company Maintains NuVasive at Buy, Raises PT from \$20 to \$27

Financial news for NUVA dated on 2012-07-25: NuVasive Guides FY Revenue \$625M, Had Seen \$615M vs \$623.2M Est

Financial news for NUVA dated on 2012-07-25: NuVasive Reports Q2 EPS \$0.27 vs \$0.23 Est; Revenues \$154.4M vs \$154.18M Est

Financial news for NUVA dated on 2012-07-02: Goldman Sachs Maintains NuVasive at Neutral, Raises PT from \$20 to \$26

Financial news for NUVA dated on 2012-06-26: Medtronic, Snyder's-Lance and Other Stocks Insiders Are Buying

Financial news for NUVA dated on 2012-06-21: Bank of America Maintains NuVasive at Buy, Raises PO from \$23 to \$26

Financial news for NUVA dated on 2012-05-01: NuVasive Trading 25.2% Higher on Heavy Volume; Currently at \$20.75

Financial news for NUVA dated on 2012-05-01: NuVasive Up 20% After Q1 Earnings

Financial news for NUVA dated on 2012-05-01: Benzinga's Top Upgrades

Financial news for NUVA dated on 2012-04-30: UPDATE: NuVasive Reports Q1 EPS \$0.2 vs \$0.18 Est; Revenues \$151.7M vs \$143.64M Est

Financial news for NUVA dated on 2012-04-30: NuVasive Reports Q1 EPS \$0.20 vs \$0.18 Est; Revs \$151.7M vs \$143.6M Est

Financial news for NUVA dated on 2012-03-09: UPDATE: Goldman Sachs Raises PT to \$16 on NuVasive

Financial news for NUVA dated on 2012-02-23: Hearing Rodman & Renshaw Making Negative Comments on Nuvasive

Financial news for NUVA dated on 2012-02-22: NuVasive Reports Q4 EPS \$0.27 vs \$0.22 Est; Revenues \$150.20M vs \$148.39M Est

Financial news for NUVA dated on 2012-02-22: Top 4 Small-Cap Stocks In The Healthcare Sector With The Highest Cash

Financial news for NUVA dated on 2012-02-13: Benzinga's Top Downgrades

Financial news for NUVA dated on 2012-01-26: Top Trade Ideas for Friday Jan 27th

Financial news for NUVA dated on 2012-01-26: Top Trade Ideas for Friday Jan 27th

Financial news for NUVA dated on 2012-01-26: Medtronic Judge Denies Nuvasive Claim Patent is Invalid

Financial news for NUVA dated on 2012-01-26: UPDATE: BMO Capital Markets Increases Target to \$16 on Nuvasive

Financial news for NUVA dated on 2012-01-25: NuVasive Halted, News Pending

Financial news for NUVA dated on 2012-01-25: Medtronic Tentatively Loses Injunction Ruling Against Nuvasive -Bloomberg

Financial news for NUVA dated on 2012-01-25: Nuvasive Spiking Higher on Heavy Volume

Financial news for NUVA dated on 2012-01-23: UPDATE: Canaccord Genuity Upgrades NuVasive to Buy, Maintains \$19 PT

Financial news for NUVA dated on 2012-01-23: Canaccord Upgrades NuVasive to Buy

Financial news for NUVA dated on 2012-01-12: Notable Call Options Activity in NuVasive

Financial news for NUVA dated on 2012-01-11: NuVasive Sees FY 2011 Revenue of \$540M vs \$538.46M Est

Financial news for NUVA dated on 2012-01-05: BMO Capital Markets Downgrades NuVasive to Market Perform

Financial news for NUVA dated on 2011-11-25: NuVasive Hits 52-Week Low of \$12.39

Financial news for NUVA dated on 2011-11-23: NuVasive Hits 52-Week Low of \$12.82

Financial news for NUVA dated on 2011-11-22: NuVasive Hits 52-Week Low of \$13.25

Financial news for NUVA dated on 2011-11-21: NuVasive Hits 52-Week Low of \$13.54

Financial news for NUVA dated on 2011-11-03: Piper Jaffray Reiterates Overweight Rating On NuVasive after Analyst Meeting

Financial news for NUVA dated on 2011-11-01: UPDATE: Rodman & Renshaw Downgrades NuVasive to Market Perform

Financial news for NUVA dated on 2011-11-01: Rodman & Renshaw Downgrades NuVasive to Market Perform, \$33 PT

Financial news for NUVA dated on 2011-10-31: Nuvasive Hits New 52-Week Low, \$14.60

Financial news for NUVA dated on 2011-10-28: BofA/Merrill Lynch Reiterates Buy Rating on Nuvasive

Financial news for NUVA dated on 2011-10-28: Nuvasive Hits New 52-Week Low, \$14.93

Financial news for NUVA dated on 2011-10-28: Bank of America Lowers PO on Nuvasive from \$40 to \$23, Maintains Buy

Financial news for NUVA dated on 2011-10-27: Nuvasive Sees 2011 EPS \$1.01-\$1.02 vs \$1.06 Est, Had Seen \$1.09-\$1.12; Revenues \$538M-\$540 vs \$538.8M Est, Had Seen \$530M-\$540M

Financial news for NUVA dated on 2011-10-27: NuVasive Reports Q3 EPS \$0.26 vs \$0.23 Est; Revenues \$132.9M vs \$134.16M Est

Financial news for NUVA dated on 2011-10-25: Zimmer Holdings Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for NUVA dated on 2011-10-10: Piper Jaffray Overweight on NuVasive

Financial news for NUVA dated on 2011-10-05: Piper Jaffray Overweight on NuVasive

Financial news for NUVA dated on 2011-09-30: Barrington Research Reiterates NuVasive Outperform, PT

Financial news for NUVA dated on 2011-09-30: J.P. Morgan Neutral on NuVasive

Financial news for NUVA dated on 2011-09-29: Afternoon Losers; Casino Stocks Getting Hit After Typhoon in China

Financial news for NUVA dated on 2011-09-29: NuVasive Signs Agreement to Acquire Impulse Monitoring

Financial news for NUVA dated on 2011-09-26: UPDATE: Jefferies Lowers Price Target on NuVasive to \$30

Financial news for NUVA dated on 2011-09-26: Jefferies Lowers PT on NuVasive to \$30

Financial news for NUVA dated on 2011-09-23: Piper Jaffray Reiterates Overweight on NuVasive

Financial news for NUVA dated on 2011-09-22: UPDATE: J.P. Morgan Lowers Price Target on NuVasive to \$24

Financial news for NUVA dated on 2011-09-22: JP Morgan Lowers PT on NuVasive to \$24

Financial news for NUVA dated on 2011-09-21: Afternoon Losers; AOL Down 12%

Financial news for NUVA dated on 2011-09-21: Rodman & Renshaw Outperform on NuVasive

Financial news for NUVA dated on 2011-09-21: Jefferies Maintains Buy on NuVasive

Financial news for NUVA dated on 2011-09-21: Benzinga's Top Pre-Market Losers

Financial news for NUVA dated on 2011-09-21: UPDATE: Piper Jaffray Lowers PT on NuVasive to \$35

Financial news for NUVA dated on 2011-09-21: J.P. Morgan Neutral on NuVasive

Financial news for NUVA dated on 2011-09-21: NuVasive Resumes Trading

Financial news for NUVA dated on 2011-09-21: NuVasive Announces Jury Verdict in Patent Case

Financial news for NUVA dated on 2011-09-21: Piper Jaffray Lowers PT on NuVasive to \$35

Financial news for NUVA dated on 2011-09-20: Jury Finds That Medtronic and Nuvasive Infringed on Each Other's Patents; Awarded Medtronic \$10.1M in Damages, Nuvasive \$660K

Financial news for NUVA dated on 2011-09-20: Trading Halted on Nuvasive; News Pending

Financial news for NUVA dated on 2011-09-16: Notable Call Options Activity in NuVasive

Financial news for NUVA dated on 2011-08-15: UPDATE: Rodman & Renshaw Upgrades NuVasive from Market Perform to Market Outperform With a PT of \$33

Financial news for NUVA dated on 2011-08-15: Rodman & Renshaw Upgrades NuVasive To Market Outperform, \$33 PT

Financial news for NUVA dated on 2011-07-26: Rodman & Renshaw Maintains NuVasive Market Perform

Financial news for NUVA dated on 2011-07-26: UPDATE: Piper Jaffray Raises PT on NuVasive to \$42

Financial news for NUVA dated on 2011-07-26: Piper Jaffray Raises PT On NuVasive To \$42

Financial news for NUVA dated on 2011-07-26: UPDATE: JP Morgan Raises PT on NuVasive from \$33 to \$34

Financial news for NUVA dated on 2011-07-26: JP Morgan Raises PT On NuVasive To \$34

Financial news for NUVA dated on 2011-07-25: NuVasive Cuts 2011 EPS Guidance to \$1.09-\$1.12 vs \$1.21 Est

Financial news for NUVA dated on 2011-07-25: UPDATE: NuVasive Cuts Guidance for Year Adjusted EPS On Conv Note Placement

Financial news for NUVA dated on 2011-07-25: NuVasive Reports Q2 EPS of \$0.30 vs. \$0.29 Est; Revenues \$133M vs. \$132.04 M Est

Financial news for NUVA dated on 2011-07-25: Earnings Scheduled For July 25

Financial news for NUVA dated on 2011-07-22: Zimmer Holdings Earnings Preview: Analysts Expect Flat Earnings, Revenue from Prior Quarter

Financial news for NUVA dated on 2011-07-21: Fifteen Health Care ETFs Trading Near 52-Week Highs

Financial news for NUVA dated on 2011-07-21: Benzinga's Top Upgrades

Financial news for NUVA dated on 2011-07-21: BMO Capital Upgrades NuVasive to Outperform from Market Perform

Financial news for NUVA dated on 2011-07-19: Earnings Preview: Stryker EPS, Revenue Expected to Rise from Previous Quarter

Financial news for NUVA dated on 2011-07-19: Robert W. Baird Upgrades NuVasive To Outperform

Financial news for NUVA dated on 2011-07-19: Benzinga's Top Upgrades

Financial news for NUVA dated on 2011-07-13: Twelve Health Care ETFs Trading Near 52-Week Highs

Financial news for NUVA dated on 2011-06-28: Top 4 NASDAQ Stocks In The Medical Instruments & Supplies Industry With The Highest Profit Margin

Financial news for NUVA dated on 2011-06-22: U.S. Stocks Rebound From Lower Open

Financial news for NUVA dated on 2011-06-21: NuVasive to Offer \$325 Million Convertible Senior Notes Due 2017

Financial news for NUVA dated on 2011-06-10: Bank of America Provides Color on NuVasive, Buy

Financial news for NUVA dated on 2011-06-08: Top 4 Small-Cap Stocks In The Medical Instruments & Supplies Industry With The Lowest PEG Ratio

Financial news for NUVA dated on 2011-05-25: Bank of America Merrill Lynch Reiterates Buy on Nuvasive

Financial news for NUVA dated on 2011-05-05: Jefferies Comments On NuVasive 1Q Results

Financial news for NUVA dated on 2011-05-05: UPDATE: J.P. Morgan Color On NUVA Target Increase

Financial news for NUVA dated on 2011-05-05: JP Morgan Raises PT On NuVasive To \$33

Financial news for NUVA dated on 2011-05-04: NuVasive Guides FY 2011 EPS \$1.20-1.23 vs. \$1.09 Estimate; Revenues \$530-540M vs. \$530.6M Est. (NUVA)

Financial news for NUVA dated on 2011-05-04: NuVasive Reports Revenues \$124.5M vs. \$123.14M Estimate (NUVA)

Financial news for NUVA dated on 2011-03-11: Piper Jaffray Reiterates Overweight Rating On NuVasive

Financial news for NUVA dated on 2011-03-04: J.P. Morgan To Adjust Ratings For NuVasive Following 4Q10 Results

Financial news for NUVA dated on 2011-02-24: Piper Jaffray Comments On NuVasive Following Recent Earnings Report

Financial news for NUVA dated on 2011-02-24: NUVA 4Q Upside Encouraging But Visibility Remains Poor, J.P. Morgan Reports

Financial news for NUVA dated on 2011-02-24: Piper Jaffray Raises PT On NuVasive To \$39

Financial news for NUVA dated on 2011-02-23: NuVasive Reports Q4 EPS of \$0.46 vs. \$0.42; Revenue \$129.3MM vs. \$125.64M

Financial news for NUVA dated on 2011-01-19: Benzinga's Volume Movers (ADTN, NUVA, CHTR, PMTC)

Financial news for NUVA dated on 2011-01-19: Benzinga's Top Pre-Market NASDAQ Gainers (NUVA, HEV, ISPH, CVVT)

Financial news for NUVA dated on 2011-01-11: Jefferies Remains Positive On NUVA, Lowers PT To \$34 From \$36

Financial news for NUVA dated on 2011-01-11: NUVA Amends 2011 Outlook, J.P. Morgan Reports

Financial news for NUVA dated on 2011-01-11: Jefferies Lowers PT On NuVasive

Financial news for NUVA dated on 2011-01-03: J.P Morgan Upgrades NuVasive To Neutral

Financial news for NUVA dated on 2011-01-03: JP Morgan Ups NUVA To Neutral

Financial news for NUVA dated on 2011-01-03: JP Morgan Upgrades NuVasive To Neutral

Financial news for NUVA dated on 2010-12-31: BTDDStocks.com Friday, December 31, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-30: BTDDStocks.com Thursday, December 30, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-29: BTDDStocks.com Wednesday, December 29, 2010

Financial news for NUVA dated on 2010-12-28: BTDDStocks.com Tuesday, December 28, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-27: BTDDStocks.com Monday, December 27, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-23: BTDDStocks.com Thursday, December 23, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-22: BTDDStocks.com Wednesday, December 22, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-21: BTDDStocks.com Tuesday, December 21, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-20: BTDDStocks.com Monday, December 20, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-17: BTDDStocks.com Friday, December 17, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-17: NuVasive Ends Friday Up 8.2% (NUVA)

Financial news for NUVA dated on 2010-12-16: BTDDStocks.com Thursday, December 16, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-15: BTDDStocks.com Wednesday, December 15, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-14: BTDDStocks.com Tuesday, December 14, 2010 End-Of-Day Update

Financial news for NUVA dated on 2010-12-13: BTDDStocks.com Monday, December 13, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-12-11: BTDDStocks.com Friday, December 10, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-12-09: BTDDStocks.com Thursday, December 9, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-12-07: BTDDStocks.com Tuesday, December 7, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-12-07: BTDDStocks.com Monday, December 6, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-12-03: BTDDStocks.com Friday, December 3, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-12-02: BTDDStocks.com Thursday, December 2, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-12-01: BTDDStocks.com Wednesday, December 1,
2010 End-Of-Day Update

Financial news for NUVA dated on 2010-11-30: BTDDStocks.com Tuesday, November 30, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-11-29: 3 Stocks That Should Rally Nicely in
2011

Financial news for NUVA dated on 2010-11-27: BTDDStocks.com Friday, November 26, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-11-24: BTDDStocks.com Wednesday, November 24,
2010 End-Of-Day Update

Financial news for NUVA dated on 2010-11-23: BTDDStocks.com Tuesday, November 23, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-11-15: BTDDStocks.com Monday, November 15, 2010
End-Of-Day Update

Financial news for NUVA dated on 2010-10-29: NuVasive Down After Earnings Miss (NUVA)

Financial news for NUVA dated on 2010-10-29: NuVasive Falls To 52-Week Low (NUVA)

Financial news for NUVA dated on 2010-10-29: J.P. Morgan Lowers Estimates, Downgrades
NuVasive Rating

Financial news for NUVA dated on 2010-10-29: Benzinga's Top Pre-Market NASDAQ Losers
(NUVA, AMAG, FSLR, CRXL)

Financial news for NUVA dated on 2010-10-28: Benzinga's After Hours Decliners (FSLR,
APKT, NUVA, AMAG, CLF, GNW)

Financial news for NUVA dated on 2010-10-05: Goldman Sachs Raises EPS Estimates On
NuVasive

Financial news for NUVA dated on 2010-09-15: Piper Jaffray Reiterates Overweight
Rating On NuVasive (NUVA)

Financial news for NUVA dated on 2010-09-15: NuVasive Hosts Analyst Meeting

Financial news for NUVA dated on 2010-09-15: Jefferies Lowers Price Target On
NuVasive (NUVA)

Financial news for NUVA dated on 2010-09-14: Benzinga's Volume Movers (NUVA, ASMI,
ZUMZ, SSRI)

Financial news for NUVA dated on 2010-09-14: Benzinga's Top Pre-Market NASDAQ Losers
(ARMH, NUVA, ARNA, THQI)

Financial news for NUVA dated on 2010-09-07: NuVasive Poised For Strong Results

Financial news for NUVA dated on 2010-08-13: NUVA's Management Remains Confident In
Its Ability To Achieve 2010 And 2011 Growth Goals

Financial news for NUVA dated on 2010-07-28: Piper Jaffray Reiterates Overweight
Rating on NuVasive (NUVA)

Financial news for NUVA dated on 2010-07-20: Stocks Falling On Unusual Volume (NUVA, MANT)

Financial news for NUVA dated on 2010-06-17: NuVasive (NUVA) Gets Buy Rating

Financial news for NUVA dated on 2010-06-03: NuVasive to Present at the Goldman Sachs Healthcare Conference and the William Blair Growth Stock Conference (NUVA)

Financial news for NUVA dated on 2010-04-21: Needham Bullish On NuVasive (NUVA)

Financial news for NUVA dated on 2010-04-19: Needham Rates NuVasive A Strong Buy (NUVA)

Financial news for NUVA dated on 2010-02-26: NuVasive, Inc.'s (NUVA) Fourth-Quarter Review

Financial news for NUVA dated on 2010-02-26: PiperJaffray Lowers NuVasive (NUVA) Price Target, Reiterates Overweight Rating

Financial news for NUVA dated on 2010-02-02: NuVasive (NUVA) Maintains Its Rating From Barclays

Financial news for NUVA dated on 2010-02-02: Genentech Inc. (DNA) Faces A Double Whammy - CNBC

Financial news for NUVA dated on 2010-01-22: Jefferies Initiates Coverage Of NuVasive With A Buy (NUVA)

Financial news for NUVA dated on 2009-12-01: NUVA's Business Momentum Remains Intact

Financial news for NUVA dated on 2009-12-01: NuVasive: Concerns Over Reimbursement Overblown

Financial news for NUVA dated on 2009-12-01: Benzinga's Top Downgrades (CHD, NUVA, NFLX)

Financial news for NUVA dated on 2009-12-01: Benzinga's Top Pre- Market Losers (LTON, OVTI, LINC, NLST, HGSI, NUVA, AFFX)

Financial news for NUVA dated on 2009-11-25: Benzinga's Volume Movers (APWR, HAYN, BCSI, NUVA)